GOLD-2014

(SPARK): a randomised, double blind, parallel group study. Lancet Respir Med 2013;1:199–209

562.Tse HN, Raiteri L, Wong KY, Yee KS, Ng LY, Wai KY, Loo CK, Chan MH. High dose N acetylcysteine in stable COPD: the 1 year, double blind, randomized, placebo controlled HIACE study. Chest 2013 Jul;144(1):106 18.

563.Egan C, Deering BM, Blake C, Fullen BM, McCormack NM, Spruit MA, Costello RW. Short term and long term effects of pulmonary rehabilitation on physical activity in COPD. Respir Med 2012 Dec;106(12):1671 9.

564.Ferreira IM, Brooks D, White J, Goldstein R. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012

Dec 12;12:CD000998.

565.Gagnon P, Saey D, Provencher S, Milot J, Bourbeau J, Tan WC, Martel S, Maltais F. Walking exercise response

to bronchodilation in mild COPD: a randomized trial. Respir Med 2012 Dec;106(12):1695 705.

566.Bischoff EW, Akkermans R, Bourbeau J, van Weel C, Vercoulen JH, Schermer TR. Comprehensive self management

and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial. BMJ 2012 Nov 28;345:e7642.

567.Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013

Jun 5;309(21):2223 31.

568.Edwards L, Shirtcliffe P, Wadsworth K, Healy B, Jefferies S, Weatherall M, Beasley R; Magnesium COPD Study Team. Use of nebulised magnesium sulphate as an adjuvant

in the treatment of acute exacerbations of COPD in adults: a randomised double blind placebo controlled trial. Thorax 2013 Apr;68(4):338 43.

569.Vollenweider DJ, Jarrett H, Steurer Stey CA, Garcia Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012

Dec 12;12:CD010257.

570.Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in exacerbations of COPD: a systematic review

and metaanalysis. Chest 2009 Mar;135(3):786 93.

571.Gunen H, Gulbas G, In E, Yetkin O, Hacievliyagil SS. Venous thromboemboli and exacerbations of COPD. Eur Respir J 2010;35(6):1243 8.

572.Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Venous thromboembolism prophylaxis

in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011 Nov 1;155(9):625 32.

573.Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al; American College of Chest Physicians. Prevention of VTE

in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence Based Clinical Practice Guidelines. Chest 2012 Feb;141(2 Suppl):e195S 226S.

574.Bertoletti L, Quenet S, Laporte S, Sahuquillo JC, Conget F, Pedrajas JM, Martin M, Casado I, Riera Mestre A, Monreal M; RIETE Investigators. Pulmonary embolism and 3 month outcomes in 4036 patients with venous thromboembolism

and chronic obstructive pulmonary disease: data from the RIETE registry. Respir Res 2013 Jul 18;14:75.

575.Cartwright M, Hirani SP, Rixon L, Beynon M, Doll H, Bower P, et al; Whole Systems Demonstrator Evaluation Team. Effect of telehealth on quality of life and psychological outcomes over 12 months (Whole Systems Demonstrator telehealth questionnaire study): nested study of patient reported outcomes in a pragmatic, cluster randomised controlled trial. BMJ 2013 Feb 26;346:f653.

576.Henderson C, Knapp M, Fernandez JL, Beecham J, Hirani SP, Cartwright M, et al; Whole System Demonstrator evaluation team. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation

in a pragmatic, cluster randomised controlled trial. BMJ 2013 Mar 20;346:f1035.

577.Pinnock H, Hanley J, McCloughan L, Todd A, Krishan A, Lewis S, et al. Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation

of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial. BMJ 2013 Oct 17;347:f6070.

578.Almagro P, Cabrera FJ, Diez J, Boixeda R, Alonso Ortiz MB, Murio C, Soriano JB; Working Group on COPD, Spanish Society of Internal Medicine. Comorbidities and short term prognosis in patients hospitalized for acute exacerbation of COPD:

the EPOC en Servicios de medicina interna (ESMI) study. Chest 2012 Nov;142(5):1126 33.

579.Mainguy V, Girard D, Maltais F, Saey D, Milot J, Senechal M, Poirier P, Provencher S. Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease. Am J Cardiol 2012 Jul 15;110(2):258 63.

580.Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between beta blocker therapy

and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012 Nov;67(11):977 84.

581.O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000;558:635 642.

582.Patel IS, Vlahos I, Wilkinson TMA, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;1704:400 407.

~

583. Martinez Garcia MA, de la Rosa Carrillo D, Soler Cataluna JJ, Donat Sanz Y, Serra PC, Lerma MA, Ballestin J, Sanchez IV, Selma Ferrer MJ, Dalfo AR, Valdecillos MB. Prognostic value of bronchiectasis in patients with moderate to severe chronic

obstructive pulmonary disease. Am J Respir Crit Care Med 2013 Apr 15;187(8):823 31.